Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Vicarious Surgical Inc. (RBOT) Form 3 filed for Joseph Edward Doherty dated 06/27/2025 lists his relationship to the issuer as a Director and states that no securities are beneficially owned by the reporting person. The filing includes a Power of Attorney (Exhibit 24.1) and is signed by an attorney-in-fact on 10/02/2025. This is an initial Section 16 filing that records ownership status rather than a transaction.
Vicarious Surgical Inc. reported a leadership change on its board of directors. On September 25, 2025, the board appointed Joseph Doherty to serve as Chairman of the Board. He joined the board earlier in the year following his election at the annual meeting of stockholders held on June 27, 2025.
Doherty already serves as a member of the board’s Compensation Committee and as Chairman of the Nominating and Corporate Governance Committee, indicating an active role in executive pay decisions and board oversight. The company also issued a press release announcing his appointment, which is furnished as an exhibit but is not considered filed for liability purposes under securities laws.
Vicarious Surgical, Inc. filed a Form 8-K reporting a material event that attaches an Investor Presentation as Exhibit 99.1 and includes the interactive cover page XBRL file. The filing lists trading symbols for the company’s common stock and warrants on the New York Stock Exchange, including warrants to purchase one share of Class A common stock at an exercise price of $11.50 per share (symbol RBOT WS). The document is signed by Stephen From, Chief Executive Officer. The filing text supplied is brief and contains exhibit and header details without additional financial tables, transaction terms, or earnings information.
Vicarious Surgical Inc. (RBOT) filing a Form 144 notifies proposed sale of 40,427 shares of Class A common stock through two brokers for planned sale on 09/22/2025. The shares break down as 32,469 with Interactive Brokers (aggregate market value $189,943.65) and 7,958 with UBS Financial Services (aggregate market value $46,554.30), against 5,298,253 shares outstanding. The reporting person acquired a total of 45,339 shares over multiple dates via distributions and vesting from 2021–2024. In the prior three months the filer sold 4,912 shares for gross proceeds of $31,540.00. The signer certifies no undisclosed material adverse information.
Vicarious Surgical Inc. filed an 8-K reporting a material event dated September 12, 2025. The filing lists corporate identifiers and contact details and shows trading symbols RBOT and RBOT WS on the New York Stock Exchange. It discloses warrants exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. The form is signed by Stephen From, Chief Executive Officer. The filing contains limited narrative or financial detail beyond the warrant description and administrative information.
Vicarious Surgical Inc. filed a current report to let investors know it has updated its investor presentation as of September 8, 2025. Senior management plans to use this updated presentation in meetings with investors and analysts, including at the H.C. Wainwright 27th Annual Global Investment Conference in New York, where Chief Executive Officer Stephen From is scheduled to present at approximately 9:00 a.m. Eastern Time on September 10, 2025.
The updated investor presentation is available on the company’s investor relations website and is also furnished as Exhibit 99.1 to this report. The company notes that the presentation is furnished, not filed, which means it is not subject to certain liability provisions of the Securities Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced.
Adam David Sachs, a director, 10% owner and President of Vicarious Surgical Inc. (RBOT), reported a non-discretionary sale on 09/03/2025 of 463 shares of Class A common stock to satisfy tax-withholding obligations from restricted stock units granted on June 2, 2023. The transactions were executed as a "sell-to-cover" under the companys equity plan at a weighted average price of $5.7564 per share (trades ranged from $5.64 to $5.87). After the sale, the reporting person beneficially owned 49,164 shares directly. The Form 4 was submitted by an attorney-in-fact on 09/04/2025.
Vicarious Surgical Inc. (RBOT) Form 4: insider sale to cover taxes
Khalifa Sammy, listed as Chief Technology Officer, Director and a 10% owner, reported a sale of 239 shares of Class A common stock on 09/03/2025 at a weighted average price of $5.7195 per share. The filing states the sale was a mandatory "sell to cover" to satisfy tax withholding on restricted stock units granted June 2, 2023, and therefore was not a discretionary trade. After the transaction, the reporting person beneficially owned 34,515 shares. The filer signed via attorney-in-fact on 09/04/2025.
Form 144 filed for Vicarious Surgical Inc. (RBOT) discloses a proposed sale of 463 shares of Class A common stock through UBS Financial Services on 09/03/2025 with an aggregate market value of $2,685. The filing states the shares were acquired by restricted stock lapse on 09/02/2025 and lists total shares outstanding as 5,298,253. The notice also reports three prior sales by the same person during the past three months totaling 1,559 shares with aggregate gross proceeds of $10,040. The filer affirms no undisclosed material adverse information and includes standard signature and legal attestations.
Vicarious Surgical Inc. (RBOT) Form 144 shows a proposed sale of 239 shares of Class A common stock through UBS Financial Services with an aggregate market value of $1,386 and an approximate sale date of 09/03/2025 on the NYSE. The filing reports the securities were acquired on 09/02/2025 via a restricted stock lapse from Vicarious Surgical Inc. and indicates 696 shares were acquired in that transaction.
The filing also discloses three prior sales by the listed seller, Sammy Khalifa, during the past three months: 239 shares on 06/03/2025 for $1,641, 223 shares on 06/23/2025 for $1,650, and 653 shares on 08/20/2025 for $3,801. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information about the issuer.